SARA KOFMAN

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda.

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015. This bill limits copayments, coinsurance, and other costsharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. 2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 3. Urge Congress to support HR 6, the 21st Century Cures Act. 4. Working with the CDC's National Center for Health Statistics, a division of the CDC, to better understand the current and looming data on psoriasis and psoriatic arthritis held by the NCHS to inform our research agenda. 5. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

-Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following bill: efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R.460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -Engagement with the Food and Drug Administration (FDA) on the patient focused drug development initiative in the form of submitted comments. Additional engagement with FDA dermatology staff on the latest in psoriasis research, the NPFs current focus and drug therapy development views from the patient community.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure.

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Urge Congress to support efforts that increase access to care for people with psoriasis and psoriatic arthritis by supporting the following efforts: -H.R.460: Patients' Access to Treatments Act of 2013: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-calledspecialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them. -S.1365/H.R. 2827: The Part D Beneficiary Appeals Fairness Act: Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foundation supports the Part D Beneficiary Appeals Fairness Act. The Act amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. -Ensure that Medicare Advantage networks are providing patients with adequate and timely access to providers with appropriate training and specialty expertise by copsonsoring HR.4998/S.2552

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis: H.R.460: Patients' Access to Treatments Act of 2012.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.